Filing Flows › CervoMed (CRVO) › Q4 2025 › vs Q4 2024
CervoMed (CRVO) Q4 2025 vs Q4 2024 (year over year)
CervoMed's revenue fell $2.2M (-100%) from $2.2M in Q4 2024 to $9K in Q4 2025.
CervoMed, Q4 2025: revenue $9K (-100% year over year), net loss $8.1M, operating cash flow −$6.6M. The chart draws each line against Q4 2024, the increases inside each band.
Every line
| Line | Q4 2025 | Q4 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $9K | $2.2M | −$2.2M | -100% |
| Other income, net | $244K | $535K | −$291K | -54% |
| Net loss | $8.1M | $6.7M | $1.4M | +21% |
| Costs & expenses | $8.3M | $9.4M | −$1.1M | -11% |
| Operating costs | $8.3M | $9.4M | −$1.1M | -11% |
| Research & development | $5.8M | $7.1M | −$1.3M | -18% |
| General & admin | $2.5M | $2.3M | $194K | +8% |
| Operating cash sources | $8.1M | $6.7M | $1.4M | +21% |
| Share-based compensation | $299K | $338K | −$39K | -12% |
| Working capital & other | $1.2M | −$1.7M | $2.9M | — |
| Cash used in operations | $6.6M | $8.1M | −$1.5M | -18% |
| Net loss absorbed | $8.1M | $6.7M | $1.4M | +21% |
Questions
How much did CervoMed's revenue grow year over year in Q4 2025?
CervoMed's revenue fell $2.2M (-100%) from $2.2M in Q4 2024 to $9K in Q4 2025.